A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subjects With Stargardt Disease
NCT06388083 · Belite Bio, Inc
Recruitment statusRecorded edit
− Previous value
Recruiting
+ Updated value
Active not recruiting
BLTE
Belite Bio, Inc
Company identity checked against sources
See the trials and registry edits we have linked to this sponsor, the company or organization running a study. Choose “Follow company” to add it to your watchlist and find its recorded changes in your dashboard.
3Trials in this database
7Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Adolescent Stargardt DiseaseNCT05244304 | BLTE | Phase 3 | Completed | 2025-08-04Actual |
| Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic AtrophyNCT05949593 | BLTE | Phase 3 | Active not recruiting | 2027-06-30Estimated |
| A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subjects With Stargardt DiseaseNCT06388083 | BLTE | Phase 2, Phase 3 | Active not recruiting | 2028-02Estimated |
Latest recorded trial changes
A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subjects With Stargardt Disease
NCT06388083 · Belite Bio, Inc
Primary completion dateRecorded edit
− Previous value
2027-12
+ Updated value
2028-02
Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy
NCT05949593 · Belite Bio, Inc
Recruitment statusRecorded edit
− Previous value
Recruiting
+ Updated value
Active not recruiting
Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy
NCT05949593 · Belite Bio, Inc
Primary completion dateRecorded edit
− Previous value
2027-08-31
+ Updated value
2027-06-30
Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Adolescent Stargardt Disease
NCT05244304 · Belite Bio, Inc
Recruitment statusRecorded edit
− Previous value
Active not recruiting
+ Updated value
Completed
Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Adolescent Stargardt Disease
NCT05244304 · Belite Bio, Inc
Primary completion dateRecorded edit
− Previous value
2025-08
+ Updated value
2025-08-04
Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Adolescent Stargardt Disease
NCT05244304 · Belite Bio, Inc
Completion date typeRecorded edit
− Previous value
Estimated
+ Updated value
Actual